Getty Images
Industryweek 9702 Pills

Pharma Giant Shire Buys Biotech Firm Dyax

Nov. 2, 2015
Dyax, a US company specializing in treatment for rare diseases, has developed a promising test drug treatment for a genetic inflammatory condition called HAE.

LONDON—Dublin-based pharmaceutical group Shire said Monday it had agreed to buy Dyax, a U.S. company specializing in rare diseases, for $5.9 billion (5.34 billion euros).

"This highly complementary transaction aligns with and accelerates our strategy to build a global leading biotechnology company focused on rare diseases and speciality conditions," Shire's chief executive Flemming Ornskov said in a statement outlining the deal that could rise by a further $650 million.

Dyax's chief executive, Gustav Christensen, said the "transaction will deliver substantial value" to his company's shareholders amid a sustained period of sector consolidation.

He added that the deal highlights Dyax's "shared commitment to bringing innovative medicines to patients who suffer from the devastating effects of HAE" -- described in the statement as a "rare, debilitating genetic inflammatory condition."

London-listed Shire, which is betting on success for Dyax's DX-2930 test drug treatment for HAE, added that it had not given up on trying to buy U.S. biotech firm Baxalta in a much bigger deal.

"Even with this (Dyax) transaction, we will continue to have the financial firepower to pursue other value-added strategic acquisitions, including Baxalta," Ornskov said in Monday's statement.

Shire had a $30-billion offer for Baxalta turned down by the U.S. group in August.

Copyright Agence France-Presse, 2015

Popular Sponsored Recommendations

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Guide to Turning Product Data into Profitable Content and Experiences

Sept. 11, 2023
Businesses can lose up to 9.5% of their annual revenue due to bad digital experiences. This guide highlights the need for enriched product content to deliver profitable content...

The Benefits of Continuous Thermal Monitoring

Oct. 17, 2023
Read this eBook to learn more about collecting and using data intelligently to improve performance.

State of Sales Report

Sept. 12, 2023
Discover the latest insights driving productivity and efficiency for more than 7,700 sales leaders and professionals.

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!